Receptor tyrosine kinases (RTKs) have been shown to be crucially involved in the molecular pathogenesis of NSCLCs, and epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) are widely used as an effective therapeutic option for patients with lung adenocarcinomas carrying mutant EGFR. Here, EGFR is linked to lung adenocarcinoma.